FABPulous

About:

FABPulous is an innovative healthcare company which develops and markets solutions for diagnostics in primary care and emergency medicine.

Website: http://www.fabpulous.com

Top Investors: EASME - EU Executive Agency for SMEs, Thuja Capital, NV Industriebank LIOF, Health Innovation Fund, Limburg Ventures

Description:

FABPulous is an innovative healthcare company which develops and markets solutions for diagnostics in primary care and emergency medicine. FABPulous is a company based in The Netherlands. It was spun out of Maastricht University at the end of 2008. In December 2009 FABPulous closed a first equity financing round co-led by Thuja Capital, Health Innovations, Limburg Ventures and NV Industriebank LIOF. The company has developed a technology that allows a simple, robust and ultra-rapid diluted plasma preparation from a drop of blood. This offers great advantages in the point-of-care (POC) and home testing setting, over current technology. It concerns a disposable plasma preparation device that can be integrated with many IVD detection platforms, such lateral flow devices. The first product application under development by FABPulous is a rapid test for the cardiac biomarker heart-type fatty acid binding protein (H-FABP), to aid in the first-line diagnosis of acute myocardial infarction.

Total Funding Amount:

3.43M EUR

Headquarters Location:

Maastricht, Limburg, The Netherlands

Founded Date:

2000-01-01

Contact Email:

info(AT)fabpulous.com

Founders:

Jan Glatz

Number of Employees:

1-10

Last Funding Date:

2017-10-17

IPO Status:

Private

Industries:

© 2025 bioDAO.ai